Irinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and goblet cells are altered following irinotecan treatment. Tumour-bearing Dark Agouti rats were administered a single dose of 175 mg/kg of irinotecan intraperitoneally and 0.01 mg/kg atropine subcutaneously. Experimental and untreated control rats were killed at times 6, 24, 48, 72, 96 and 120 h after treatment. Jejunum and colon samples were formalin fixed. Haematoxylin and eosin staining, Alcian Blue-PAS staining, and immunohisto...
Purpose Intestinal mucositis and the closely associated diarrhea are common costly side effects of i...
Gastrointestinal mucositis (GIM) has become increasingly recognised as a major toxicity of cancer tr...
Abstract\ud \ud Background\ud The irinotecan (CPT-11) ...
PurposeMucositis is a major oncological problem, caused by the cytotoxic effects of cancer chemother...
Chemotherapy-induced diarrhoea is a major oncological problem, caused by the cytotoxic effects of ca...
Also cited as: Proceedings of the 2010 International MASCC/ISOO Symposium held in Vancouver, Canada,...
Gastrointestinal dysfunction is a common side-effect of chemotherapy leading to dose reductions and ...
Copyright © 2007 S. Karger AG, BaselBackgroundIrinotecan is a common cytotoxic agent used in advance...
Published online: 20 September 2016Purpose: Chemotherapy-induced mucositis is characterised by damag...
The original publication can be found at www.springerlink.comPurpose The pathobiology of alimentary ...
The original publication can be found at www.springerlink.comPurpose The aetiology of mucositis is c...
<p>(<b>A</b>) Significant decrease in the number of BrdU postive cells in the small intestinal crypt...
Background The irinotecan (CPT-11) causes intestinal mucositis and diarrhea that may be related t...
Alimentary tract (AT) mucositis is a serious and debilitating side-effect of cancer therapy primaril...
Abstract Background The irinotecan (CPT-11) causes intestinal mucositis and diarrhea that may be rel...
Purpose Intestinal mucositis and the closely associated diarrhea are common costly side effects of i...
Gastrointestinal mucositis (GIM) has become increasingly recognised as a major toxicity of cancer tr...
Abstract\ud \ud Background\ud The irinotecan (CPT-11) ...
PurposeMucositis is a major oncological problem, caused by the cytotoxic effects of cancer chemother...
Chemotherapy-induced diarrhoea is a major oncological problem, caused by the cytotoxic effects of ca...
Also cited as: Proceedings of the 2010 International MASCC/ISOO Symposium held in Vancouver, Canada,...
Gastrointestinal dysfunction is a common side-effect of chemotherapy leading to dose reductions and ...
Copyright © 2007 S. Karger AG, BaselBackgroundIrinotecan is a common cytotoxic agent used in advance...
Published online: 20 September 2016Purpose: Chemotherapy-induced mucositis is characterised by damag...
The original publication can be found at www.springerlink.comPurpose The pathobiology of alimentary ...
The original publication can be found at www.springerlink.comPurpose The aetiology of mucositis is c...
<p>(<b>A</b>) Significant decrease in the number of BrdU postive cells in the small intestinal crypt...
Background The irinotecan (CPT-11) causes intestinal mucositis and diarrhea that may be related t...
Alimentary tract (AT) mucositis is a serious and debilitating side-effect of cancer therapy primaril...
Abstract Background The irinotecan (CPT-11) causes intestinal mucositis and diarrhea that may be rel...
Purpose Intestinal mucositis and the closely associated diarrhea are common costly side effects of i...
Gastrointestinal mucositis (GIM) has become increasingly recognised as a major toxicity of cancer tr...
Abstract\ud \ud Background\ud The irinotecan (CPT-11) ...